Literature DB >> 17293689

Aldosterone, mineralocorticoid receptors, and vascular inflammation.

Anette Fiebeler1, Dominik N Muller, Erdenechimeg Shagdarsuren, Friedrich C Luft.   

Abstract

PURPOSE OF REVIEW: Aldosterone and its mineralocorticoid receptor represent an ancient signaling system. Indeed, the mineralocorticoid receptor is older than its agonist. Both have probably served various functions through the eons and salt preservation may be relatively recent. A large body of evidence suggests that aldosterone conducts signaling in vascular cells and contributes substantially to vascular remodeling and target organ damage. A blood pressure and salt balance-independent effect was first observed in two large heart failure trials. RECENT
FINDINGS: Mineralocorticoid receptor blockade has now been shown to reduce proteinuria even in the face of angiotensin converting enzyme inhibition and AT1 receptor blockade. Mineralocorticoid receptor blockade effectively reduces target organ damage in every hypertensive model tested, irrespective of circulating renin and aldosterone levels. Protection is also observed in nonhypertensive diabetic and hyperlipidemic models. Signaling in vascular cells involves primarily the mitogen activated protein kinase pathway with participation of the epidermal growth factor receptor. Novel signaling molecules have been shown to participate in aldosterone-mediated actions including the murine double-minute type 2 protein that participates in antiapoptotic and proliferative effects. Clinically, mutations in the mineralocorticoid receptor have shed additional light on its importance.
SUMMARY: A resurgence of interest in aldosterone reflects its importance and clinical relevance for vascular remodeling and target organ damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293689     DOI: 10.1097/MNH.0b013e32801245bb

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  7 in total

Review 1.  Aldosterone blockade in chronic kidney disease: can it improve outcome?

Authors:  Robert D Toto
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

2.  Eplerenone inhibits aldosterone-induced renal expression of cyclooxygenase.

Authors:  Ma Bayorh; A Rollins-Hairston; J Adiyiah; D Lyn; D Eatman
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2012-05-03       Impact factor: 1.636

3.  Involvement of Depressive Catecholamines as Thrombosis Risk/Inflammatory Markers in Non-Smoker, Non-Obese Congestive Heart Failure, Linked to Increased Epidermal Growth Factor-Receptor (EGF-R) Production.

Authors:  Nadia M Hamdy; Lamiaa El-Wakeel; Salwa M Suwailem
Journal:  Indian J Clin Biochem       Date:  2011-01-13

4.  Aldosterone activates endothelial exocytosis.

Authors:  Youngtae Jeong; Damian F Chaupin; Kenji Matsushita; Munekazu Yamakuchi; Scott J Cameron; Craig N Morrell; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-17       Impact factor: 11.205

5.  The involvement of prostaglandins in the contractile function of the aorta by aldosterone.

Authors:  Danita Eatman; Katie Peagler; Jana Watson; Aisha Rollins-Hairston; Mohamed A Bayorh
Journal:  BMC Res Notes       Date:  2011-04-14

6.  The aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitis.

Authors:  Elodie Bousquet; Min Zhao; André Ly; Guillaume Leroux Les Jardins; Brigitte Goldenberg; Marie-Christine Naud; Laurent Jonet; Bernadette Besson-Lescure; Frederic Jaisser; Nicolette Farman; Yvonne De Kozak; Francine Behar-Cohen
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

7.  An emerging concept of vascular salt sensitivity.

Authors:  Kristina Kusche-Vihrog; Hans Oberleithner
Journal:  F1000 Biol Rep       Date:  2012-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.